2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5689 NSD2 is a potent vaccine target for immunotherapy of multiple myeloma

Majid Asgari, PhD, Hongwei Xu, MD2, Zijun Zhang, PhD3, Yan Cheng, PhD4, David E. Mery, PhD5, Yamin Meng, PhD6, MIN Yang, PhD7, Jieqiong Zhou, MD8, Seth Eubanks9, Yong Li, PhD10, Ken H. H. Young Jr, MD, PhD11, Eric Siegel, MS12, Carolina D Schinke, MD13, Frits van Rhee, MD, PhD14, John D Shaughnessy, Jr, PhD15, Guido Tricot, MD/PhD16, Fenghuang Zhan, MD/PhD17
1 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
2 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
3 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
4 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
5 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
6 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
7 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
8 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
9 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
10 Baylor College of Medicine, Houston, United States
11 Duke University Medical Center, Durham, United States
12 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
13 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
14 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
15 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
16 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States
17 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, Little Rock, Arkansas, United States

Background: Nuclear receptor-binding SET domain protein 2 (NSD2/MMSET/WHSC1) is a histone methyltransferase that is aberrantly overexpressed in t(4;14)-positive multiple myeloma patients. Aggressive disease is linked to NSD2-driven chromatin reprogramming, which promotes malignant transcriptional programs. This strongly suggests that NSD2 is a target for T-cell-directed vaccination, as intracellular oncogenic proteins can be processed and presented by major histocompatibility complex class I molecules. We have developed a DNA vaccine targeting NSD2 and tested its immunogenicity and antitumor effects in preclinical multiple myeloma models.

Methods: The NSD2 DNA vaccine was administered both alone and in combination with an immunostimulatory adjuvant to immunocompetent mice that did not have tumors. Serum was evaluated for anti-NSD2 antibodies, immunoglobulin subclasses, and interferon-γ (IFN-γ). Splenic CD8? T cells were isolated and co-cultured with NSD2-high or NSD2-low myeloma cells. Mice were challenged with tumors systemically and treated with a control, vaccine, or vaccine with adjuvant. Survival was determined, and immune cell populations in the spleen and bone marrow were analyzed by multiparametric flow cytometry.

Results: Vaccination induced anti-NSD2 antibodies and increased both relevant immunoglobulin subclasses and circulating IFN-γ, indicating a coordinated humoral and Th1-associated immune response. CD8? T cells from vaccinated mice exhibited significantly greater cytotoxicity against NSD2-overexpressing target cells than against low-NSD2-expressing control cells. Furthermore, vaccine-primed T cells showed increased proliferation when exposed to NSD2+ target cells. In the systemic tumor challenge model, both vaccine-containing treatments increased survival and remained separated from the control survival curve. Immune profiling of the vaccine groups showed increased frequencies of CD3+, CD4+, and CD8+ T cells, DCs, NK cells, and macrophages in the spleen and bone marrow. Splenic IFN-γ? CD4? and CD8? T cells were also increased.

Conclusions: NSD2-directed DNA vaccination generated coordinated humoral and cellular immunity, significant cytotoxicity against NSD2-high myeloma cells, remodeling of splenic and bone marrow immune compartments, and prolonged survival following tumor challenge. These findings confirm NSD2 as an immunogenic target and support further development of NSD2-directed vaccination for NSD2-high, including t(4;14)-positive, multiple myeloma.

Majid Asgari, PhD: No relevant conflicts of interest to declare.